<DOC>
	<DOCNO>NCT02601001</DOCNO>
	<brief_summary>The purpose study evaluate PK , safety tolerability omecamtiv mecarbil healthy volunteer .</brief_summary>
	<brief_title>Safety Study Omecamtiv Mecarbil Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>No history evidence clinically relevant medical disorder determine Investigator , good health determine prestudy physical examination medical history clinically significant abnormality , normal vital sign history presence clinically significant abnormal electrocardiogram find Subjects ' prestudy clinical laboratory finding ( include creatine phosphokinase ) within normal range outside normal range , deem clinically significant Investigator A clinically significant disorder/disease , include gastro intestinal abnormality might interfere absorption An unstable medical condition , define hospitalize within 28 day day 1 , major surgery within 6 month day 1 , otherwise unstable judgment Investigator History evidence clinically significant disorder , condition , disease , opinion Investigator Medical Monitor would pose risk subject safety interfere study evaluation , procedure , completion History malignancy type surgically excise nonmelanomatous skin cancer situ cervical cancer within 5 year day dose Use prescription overthecounter medication within 14 day 5 halflives ( whichever time period great ) , prior receive first dose omecamtiv mecarbil ( Acetaminophen 2 gram per day analgesia hormone replacement therapy ( e.g. , estrogen ) allow Use known inhibitor CYP3A4/pglycoprotein ( Pgp ) CYP2D6 within 14 day 5 halflives , whichever longer ; use grapefruit juice grapefruit containing product within 7 day prior receive first dose omecamtiv mecarbil Use know CYP3A4 inducer within 30 day 5 halflives , whichever longer , receive omecamtiv mecarbil</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>